FDA Links Hydroxycut Weight Loss Supplements to Liver Damage
Manufacturer Recalls More Than a Dozen Products
By News Staff
5/6/2009
Katz said several additional cases of liver failure resolved when patients stopped taking Hydroxycut.
In conjunction with the FDA warning, Iovate Health Sciences Inc., of Oakville, Ontario, and Iovate Health Sciences USA Inc. of Blasdell, N.Y., makers of Hydroxycut products, announced a recall of more than a dozen of the weight loss products from the market.
"Although the liver damage appears to be relatively rare, FDA contends the consumer should not be exposed to unnecessary risk," Katz said. "FDA continues to investigate the potential relationship between the use of Hydroxycut dietary supplements and liver injury and other potentially serious side effects."
Katz said the FDA has not determined which Hydroxycut ingredient dosages may be associated with the risk of developing liver disease. She said there were overlapping ingredients in the recalled products, but no single ingredient was common to all the products.
The FDA is advising consumers to discontinue use of Hydroxycut weight loss products and to consult a physician if they are experiencing any symptoms of liver injury, including jaundice, brown urine, nausea, vomiting, light colored stools, unusual tiredness, weakness, stomach or abdominal pain, unexplained itching, and loss of appetite. Other health problems related to the use of Hydroxycut products reported to the FDA include seizures, cardiovascular disorders and rhabdomyolysis.
Physicians or patients should report any adverse events associated with the use of dietary supplements to the FDA's MedWatch Program online or by calling (800) 332-1088.
Hydroxycut's Cleanse and Hoodia products are not affected by the recall.
Recent Decline in U.S. Smoking Prevalence Stalls
USPSTF Revamps Breast Cancer Screening Recommendations
New Report Sounds 'Call to Revolutionize Chronic Pain Care'
AAFP Offers Guidance on FDA Tobacco Regulation
Focus Groups Reveal Physician Concerns About Comparative Effectiveness Research
Manufacturer Recalls Millions of Insulin Syringes
Second Grant to be Used for More Children's Healthy Lifestyles Books
AAFP, Others Reiterate Need for Flu Vaccines in Pregnant Women
Study Suggests Cost for Universal Coverage Misleading
FDA Warns of Adverse Events With Gentamicin Ophthalmic Ointment Use
AAFP, Other Organizations Urge Pregnant Women to Get Flu Vaccines
Physicians Should Recall Children in Need of Hib Booster Dose
AAFP Invites Members to Sign Up for Health Care Notification Network
Online System Delivers Safety Alerts Faster Than Standard Mail, Fax
(4/22/2009)
FDA Requires Boxed Warning for Metoclopramide Products
Chronic Use Linked to Tardive Dyskinesia
(3/11/2009)
FDA Issues Health Advisory for Raptiva
Psoriasis Drug Associated With Three Deaths
(2/24/2009)
More From AAFP
American Family Physician
Few Data on Dietary Supplements for Sustained Weight Loss
(Sept. 15, 2004)








